Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    A site-wide banner about NIH’s terminology transition and related updates is no longer displayed.
    Difference
    1%
    Check dated 2026-11-07T14:11:52.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0 while the page continued to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-31T14:58:12.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition from the term “Artificial Intelligence” to “Super Intelligence” and links to updates about the change. It appears above the study record’s 403 error.
    Difference
    1%
    Check dated 2026-10-24T14:28:06.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T14:11:35.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T14:23:11.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden message, preventing access to the trial details.
    Difference
    18%
    Check dated 2026-09-19T20:22:46.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.